Arcus Biosciences, Inc.

NYSE:RCUS

Biotechnology

Healthcare
$15.78 -0.39%

-$0.09 today

Market cap
$2.27B
Beta
0.84
P/E (TTM)
-8.2
EPS (TTM)
-$2.94
52W Low $7.91High $28.72

Volume 1.07M

Average 1.17M

Big Five Numbers

Arcus Biosciences, Inc. growth analysis

Start with the long-run numbers that show whether RCUS compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/A+30.2%-4.3%
Equity
N/AN/A-13.6%+9.1%
Cash
N/AN/A+2.5%+48.0%
ROIC
N/A-26.9%-38.0%-41.9%

Analysis

Latest growth is strongest in Cash at +48.0% and weakest in ROIC at -41.9%. Three-year average ROIC is -38.0%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A+30.2%
+30.1% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +30.2% over three years. Forward estimates point to Revenue at +30.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where RCUS earns its revenue, as reported in company filings

  • License And Development Services
  • Development Services
  • R&D Services
  • License
  • Gilead License to Domvanalimab
  • License and Development Services Revenue
  • Other
Revenue by segment for FY2025
Segment · FY2025 Revenue Share YoY
License And Development Services$221M87.4%—
Development Services$17M6.7%—
R&D Services$8M3.2%—
License$7M2.8%—

Figures in USD. Segments account for 102.4% of reported FY2025 revenue; -$6M is not attributed to a segment. Smaller segments are grouped as "Other".

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$353.0M
+ D&A$10.0M
+ Stock-Based Comp$60.0M
+ Deferred Tax$0
- Working Capital-$194.0M
- Other Non-Cash-$5.0M
= Operating Cash Flow-$482.0M
- Capex-$2.0M
= Free Cash Flow-$484.0M

Analysis

FY2025 free cash flow is -$484.0M. FCF conversion is 137.1% of net income. Operating cash flow was -$482.0M, with capex of -$2.0M. The largest bridge item is Working Capital at -$194.0M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for RCUS.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for RCUS.

Sign in free

Competitor growth

How does Arcus Biosciences, Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

ImmunityBio, Inc.

IBRX

$6.40B+85.4%+184.8%+678.6%
+86.0% (5yr)1 analysts

Liquidia Corporation

LQDA

$5.17B—+192.5%+115.0%
+50.6% (5yr)2 analysts

Cogent Biosciences, Inc.

COGT

$4.97B———
—5 analysts

Viridian Therapeutics, Inc.

VRDN

$3.51B+39.5%+132.2%+241.9%
+78.8% (5yr)5 analysts

Denali Therapeutics Inc.

DNLI

$3.00B———
—14 analysts

Beam Therapeutics Inc.

BEAM

$2.36B—+466.3%+31.9%
+33.5% (5yr)5 analysts

Agios Pharmaceuticals, Inc.

AGIO

$1.89B-0.9%—+56.0%
+72.2% (5yr)6 analysts

Ocular Therapeutix, Inc.

OCUL

$1.37B+40.3%+24.4%+0.2%
+80.5% (5yr)3 analysts

Questions

Growth questions

Common questions about RCUS's growth, answered from reported and forecast figures.

Is RCUS growing revenue?

Revenue declined 4.3% year over year, from $258.00M to $247.00M.

Is RCUS turning growth into profit?

The latest net margin is -142.9%, which shows how much revenue became net income.